The association of cytochrome 7A1 and ATP-binding cassette G8 genotypes with type 2 diabetes among Jordanian patients

Eyada Abed; Yazun Jarrar; Hussam Alhawari; Sarah Abdullah; Malek Zihlif

doi:10.1515/dmpt-2021-0164

Article

The association of cytochrome 7A1 and ATP-binding cassette G8 genotypes with type 2 diabetes among Jordanian patients

Eyada Abed , Yazun Jarrar , Hussam Alhawari , Sarah Abdullah and Malek Zihlif

Published/Copyright: November 29, 2021

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information

From the journal Drug Metabolism and Personalized Therapy Volume 37 Issue 2

Abstract

Objectives

Increased cholesterol levels were found to be associated with diabetes mellitus type II (DM2). The cholesterol is metabolized by cytochrome 7A1 (CYP7A1) and transported in the intestine by ATP-binding cassette G8 (ABCG8). Genetic variants in CYP7A1 and ABCG8 genes can affect the cholesterol levels. The aim of this study is to compare the frequency of CYP7A1 rs3808607 and ABCG8 rs11887534 and rs4148217 genotypes between healthy and DM2 subjects from Jordanian population.

Methods

A total of 117 DM2 patients and 100 healthy controls, of Jordanian Arabic origin, were genotyped for CYP7A1 rs3808607 and ABCG8 rs11887534 and rs4148217 genetic variants using polymerase chain reaction (PCR) followed by restriction fragment length polymorphism technique.

Results

The study showed that homozygosity of rs3808607 (A-204C) genotype in CYP7A1 was significantly higher in DM2 patients (ANOVA, p<0.05) with an odd ratio of 2.66, but rs11887534 (G55C) and rs4148217 (C1199A) genetic polymorphisms in ABCG8 were found in comparable frequencies in both healthy and DM2 subjects.

Conclusions

The results of this study indicate that CYP7A1 rs3808607 genetic polymorphism is associated with DM2. Further clinical studies are required to confirm this finding among DM2 patients of Jordanian origin.

Keywords: ABCG8; CYP7A1; diabetes mellitus; genetic variants; Jordan

Corresponding author: Yazun Jarrar, PhD, Department of Pharmaceutical Science, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan, E-mail: yazun.jarrar@zuj.edu.jo

Acknowledgments

The authors would like to thank Deanship of Graduate Studies, The University of Jordan, Amman, Jordan for supporting this research.

Research funding: None declared.
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
Competing interests: Authors state no conflict of interest.
Informed consent: Informed consent was obtained from all individuals included in this study.
Ethical approval: The study was approved by the Institutional Review Board of Jordan University Hospital with reference number of 67/2019/4015.

References

1. Bardini, G, Rotella, CM, Giannini, S. Dyslipidemia and diabetes: reciprocal impact of impaired lipid metabolism and Beta-cell dysfunction on micro- and macrovascular complications. Rev Diabet Stud 2012;9:82–93. https://doi.org/10.1900/rds.2012.9.82.Search in Google Scholar

2. Taylor, R. Type 2 diabetes: etiology and reversibility. Diabetes Care 2013;36:1047–55. https://doi.org/10.2337/dc12-1805.Search in Google Scholar

3. Kannel, WB. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J 1985;110:1100–7. https://doi.org/10.1016/0002-8703(85)90224-8.Search in Google Scholar

4. Cholesterol Treatment Trialists, C, Kearney, PM, Blackwell, L, Collins, R, Keech, A, Simes, J, et al.. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117–25. https://doi.org/10.1016/S0140-6736(08)60104-X.Search in Google Scholar

5. Mooradian, AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metabol 2009;5:150–9. https://doi.org/10.1038/ncpendmet1066.Search in Google Scholar PubMed

6. Schofield, JD, Liu, Y, Rao-Balakrishna, P, Malik, RA, Soran, H. Diabetes dyslipidemia. Diabetes Ther 2016;7:203–19. https://doi.org/10.1007/s13300-016-0167-x.Search in Google Scholar PubMed PubMed Central

7. Jiang, XY, Zhang, Q, Chen, P, Li, SY, Zhang, NN, Chen, XD, et al.. CYP7A1 polymorphism influences the LDL cholesterol-lowering response to atorvastatin. J Clin Pharm Therapeut 2012;37:719–23. https://doi.org/10.1111/j.1365-2710.2012.01372.x.Search in Google Scholar PubMed

8. Wei, KK, Zhang, LR, Zhang, Y, Hu, XJ. Interactions between CYP7A1 A-204C and ABCG8 C1199A polymorphisms on lipid lowering with atorvastatin. J Clin Pharm Therapeut 2011;36:725–33. https://doi.org/10.1111/j.1365-2710.2010.01227.x.Search in Google Scholar PubMed

9. Hubacek, JA, Berge, KE, Stefkova, J, Pitha, J, Skodova, Z, Lanska, V, et al.. Polymorphisms in ABCG5 and ABCG8 transporters and plasma cholesterol levels. Physiol Res 2004;53:395–401.10.33549/physiolres.930470Search in Google Scholar

10. Kajinami, K, Brousseau, ME, Nartsupha, C, Ordovas, JM, Schaefer, EJ. ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin. J Lipid Res 2004;45:653–6. https://doi.org/10.1194/jlr.m300278-jlr200.Search in Google Scholar

11. Abed, E, Jarrar, Y, Alhawari, H, Abdullah, S, Zihlif, M. How the cytochrome 7A1 (CYP7A1) and ATP-binding cassette G8 (ABCG8) genetic variants affect atorvastatin response among type 2 diabetic patients attending the University of Jordan Hospital. Int J Clin Pharmacol Therapeut 2021;59:99–108. https://doi.org/10.5414/cp203779.Search in Google Scholar

12. Umpierre, D, Ribeiro, PA, Kramer, CK, Leitao, CB, Zucatti, AT, Azevedo, MJ, et al.. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. J Am Med Assoc 2011;305:1790–9. https://doi.org/10.1001/jama.2011.576.Search in Google Scholar

13. Bochkov, VN, Oskolkova, OV, Birukov, KG, Levonen, AL, Binder, CJ, Stockl, J. Generation and biological activities of oxidized phospholipids. Antioxidants Redox Signal 2010;12:1009–59. https://doi.org/10.1089/ars.2009.2597.Search in Google Scholar

14. Srivastava, A, Choudhuri, G, Mittal, B. CYP7A1 (-204 A>C; rs3808607 and -469 T>C; rs3824260) promoter polymorphisms and risk of gall bladder cancer in North Indian population. Metabolism 2010;59:767–73. https://doi.org/10.1016/j.metabol.2009.09.021.Search in Google Scholar

15. Qrafli, M, Amar, Y, Bourkadi, J, Ben Amor, J, Iraki, G, Bakri, Y, et al.. The CYP7A1 gene rs3808607 variant is associated with susceptibility of tuberculosis in Moroccan population. Pan Afr Med J 2014;18:1. https://doi.org/10.11604/pamj.2014.18.1.3397.Search in Google Scholar

16. Fu, L, Zhao, Y, Wu, X, Liu, H, Shi, J, Lu, J, et al.. CYP7A1 genotypes and haplotypes associated with hypertension in an obese Han Chinese population. Hypertens Res 2011;34:722–7. https://doi.org/10.1038/hr.2011.18.Search in Google Scholar

17. Zhao, GX, Liu, Y, Li, ZX, Lv, CZ, Traboulsee, A, Sadovnick, AD, et al.. Variants in the promoter region of CYP7A1 are associated with neuromyelitis optica but not with multiple sclerosis in the Han Chinese population. Neurosci Bull 2013;29:525–30. https://doi.org/10.1007/s12264-013-1347-6.Search in Google Scholar

18. Al-sheikh, NM, El-Hefnway, SM, El-Shetahy, AA. Cholesterol 7-alpha hydroxylase gene (CYP7A1) promoter polymorphism rs3808607 as a risk factor for pulmonary tuberculosis in Egypt. Meta Gene 2018;16:66–71. https://doi.org/10.1016/j.mgene.2018.01.012.Search in Google Scholar

19. Renner, O, Lutjohann, D, Richter, D, Strohmeyer, A, Schimmel, S, Muller, O, et al.. Role of the ABCG8 19H risk allele in cholesterol absorption and gallstone disease. BMC Gastroenterol 2013;13:30. https://doi.org/10.1186/1471-230x-13-30.Search in Google Scholar

20. Koeijvoets, KC, van der Net, JB, Dallinga-Thie, GM, Steyerberg, EW, Mensink, RP, Kastelein, JJ, et al.. ABCG8 gene polymorphisms, plasma cholesterol concentrations, and risk of cardiovascular disease in familial hypercholesterolemia. Atherosclerosis 2009;204:453–8. https://doi.org/10.1016/j.atherosclerosis.2008.09.018.Search in Google Scholar

21. Hubacek, JA, Pitha, J, Skodova, Z, Poledne, R, Lanska, V, Waterworth, DM, et al.. Polymorphisms in CYP-7A1, not APOE, influence the change in plasma lipids in response to population dietary change in an 8 year follow-up; results from the Czech MONICA study. Clin Biochem 2003;36:263–7. https://doi.org/10.1016/s0009-9120(03)00025-0.Search in Google Scholar

22. Milanizadeh, S, Mohebbi, SR, Khanyaghma, M, Mohammad Alizadeh, AH. ATP binding cassette and cholecystokinin A receptor genetic variations in gallstone susceptibility. Gastroenterol Hepatol Bed Bench 2017;10:S108–16.Search in Google Scholar

23. Grunhage, F, Acalovschi, M, Tirziu, S, Walier, M, Wienker, TF, Ciocan, A, et al.. Increased gallstone risk in humans conferred by common variant of hepatic ATP-binding cassette transporter for cholesterol. Hepatology 2007;46:793–801. https://doi.org/10.1002/hep.21847.Search in Google Scholar PubMed

24. Li, Q, Wei, XL, Yin, RX. Association of ATP binding cassette transporter G8 rs4148217 SNP and serum lipid levels in Mulao and Han nationalities. Lipids Health Dis 2012;11:46. https://doi.org/10.1186/1476-511x-11-46.Search in Google Scholar PubMed PubMed Central

25. Plat, J, Bragt, MC, Mensink, RP. Common sequence variations in ABCG8 are related to plant sterol metabolism in healthy volunteers. J Lipid Res 2005;46:68–75. https://doi.org/10.1194/jlr.m400210-jlr200.Search in Google Scholar

26. Bertoluci, MC, Rocha, VZ. Cardiovascular risk assessment in patients with diabetes. Diabetol Metab Syndrome 2017;9:25. https://doi.org/10.1186/s13098-017-0225-1.Search in Google Scholar PubMed PubMed Central

27. Alhawari, H, Jarrar, Y, AlKhatib, MA, Alhawari, H, Momani, M, Zayed, A, et al.. The association of 3-hydroxy-3-methylglutaryl-CoA reductase, apolipoprotein E, and solute carrier organic anion genetic variants with atorvastatin response among Jordanian patients with type 2 diabetes. Life (Basel) 2020;10:232. https://doi.org/10.3390/life10100232.Search in Google Scholar PubMed PubMed Central

28. Cavaiola, TS, Pettus, JH. Management of type 2 diabetes: selecting amongst available pharmacological agents. In: Feingold, KR, Anawalt, B, Boyce, A, Chrousos, G, de Herder, WW, Dhatariya, K, editors, et al.. South Dartmouth (MA): Endotext; 2000.Search in Google Scholar

29. Elnaem, MH, Mohamed, MHN, Huri, HZ, Azarisman, SM, Elkalmi, RM. Statin therapy prescribing for patients with type 2 diabetes mellitus: a review of current evidence and challenges. J Pharm BioAllied Sci 2017;9:80–7. https://doi.org/10.4103/jpbs.JPBS_30_17.Search in Google Scholar PubMed PubMed Central

30. Kim, SK, Yim, SV, Lee, BC. Association between cytochrome P450 promoter polymorphisms and ischemic stroke. Exp Ther Med 2012;3:261–8. https://doi.org/10.3892/etm.2011.388.Search in Google Scholar PubMed PubMed Central

31. Jarrar, YB, Balasmeh, AA, Jarrar, W. Sequence analysis of the N-acetyltransferase 2 gene (NAT2) among Jordanian volunteers. Libyan J Med 2018;13:1408381. https://doi.org/10.1080/19932820.2017.1408381.Search in Google Scholar PubMed PubMed Central

32. Hakooz, N, Jarrar, YB, Zihlif, M, Imraish, A, Hamed, S, Arafat, T. Effects of the genetic variants of organic cation transporters 1 and 3 on the pharmacokinetics of metformin in Jordanians. Drug Metab Pers Ther 2017;32:157–62. https://doi.org/10.1515/dmpt-2017-0019.Search in Google Scholar PubMed

33. Matthan, NR, Pencina, M, LaRocque, JM, Jacques, PF, D’Agostino, RB, Schaefer, EJ, et al.. Alterations in cholesterol absorption/synthesis markers characterize Framingham offspring study participants with CHD. J Lipid Res 2009;50:1927–35. https://doi.org/10.1194/jlr.p900039-jlr200.Search in Google Scholar

34. Nicolas, A, Fatima, S, Lamri, A, Bellili-Munoz, N, Halimi, JM, Saulnier, PJ, et al.. ABCG8 polymorphisms and renal disease in type 2 diabetic patients. Metabolism 2015;64:713–9. https://doi.org/10.1016/j.metabol.2015.03.005.Search in Google Scholar PubMed

35. Srivastava, A, Garg, N, Srivastava, A, Srivastava, K, Mittal, B. Effect of genetic variant (rs11887534) in ABCG8 gene in coronary artery disease and response to atorvastatin therapy. Dis Markers 2010;28:307–13. https://doi.org/10.1155/2010/357304.Search in Google Scholar

Received: 2021-07-14

Accepted: 2021-09-20

Published Online: 2021-11-29

You are currently not able to access this content.

Articles in the same Issue

https://doi.org/10.1515/dmpt-2021-0164

Keywords for this article

ABCG8; CYP7A1; diabetes mellitus; genetic variants; Jordan